Pharma: Page 12
-
Permission granted by Immunic Therapeutics
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
By Alexandra Pecci • Aug. 13, 2024 -
Stock via Getty Images
M&A is ready to explode, and that’s good news for pharma layoffs
Deals driven by obesity meds are fueling an M&A comeback, driving the industry to take fewer cost-cutting measures.
By Kelly Bilodeau • Aug. 12, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024 -
Courtesy of Roche
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
By Jacob Bell • Aug. 8, 2024 -
Mario Tama / Getty via Getty Images
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.
By Michael Gibney • Aug. 8, 2024 -
Permission granted by Moderna
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
By Michael Gibney • Aug. 6, 2024 -
Stock via Getty Images
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
By Kelly Bilodeau • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Drew Angerer via Getty Images
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.
By Jonathan Gardner • Aug. 1, 2024 -
Stock via Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024 -
Spencer Platt / Staff via Getty Images
3 Big Pharma cancer drugs facing inflation penalties
The U.S. government will demand payment from Big Pharma to make up for dozens of drugs with prices that rose faster than the rate of inflation.
By Amy Baxter • July 31, 2024 -
Permission granted by Sanofi
7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run
Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.
By Michael Gibney • July 30, 2024 -
Permission granted by Biogen
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.
By Amy Baxter • July 29, 2024 -
Stock via Getty Images
Citius’ first FDA decision date is approaching — and its CEO has millions on the line
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.
By Amy Baxter • July 26, 2024 -
Permission granted by Mubadala Capital
Q&AIn biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
By Meagan Parrish • July 25, 2024 -
Chris duMond via Getty Images
Where Kamala Harris stands on three key pharma issues
The presumptive Democratic nominee has a long history of taking on pharma over drug prices and supporting women’s healthcare access.
By Amy Baxter • July 24, 2024 -
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 23, 2024 -
Alex Wong / Staff via Getty Images
Q&ABird flu puts BARDA back in the spotlight
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.
By Alexandra Pecci • July 23, 2024 -
Stock via Getty Images
To overcome barriers, cell and gene therapies need outside support
With great potential in cell and gene therapies, there are still plenty of barriers to getting the breakthroughs to patients.
By Kelly Bilodeau • July 22, 2024 -
Stock via Getty Images
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
By Amy Baxter • July 19, 2024 -
Justin Sullivan via Getty Images
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
By Ned Pagliarulo • July 19, 2024 -
Permission granted by Gilead
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.
By Michael Gibney • July 18, 2024 -
Permission granted by Amylyx
Q&AAmylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
By Meagan Parrish • July 17, 2024 -
Getty Images via Getty Images
Has pharma emerged from the ‘age of uncertainty’?
An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.
By Michael Gibney • July 16, 2024 -
Courtesy of BMS
BMS’ long-standing leukemia blockbuster stares down its first generic
Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.
By Amy Baxter • July 12, 2024
Previous
